Back to discover
Drug

Lisinopril

In clinical development
ClassAngiotensin-converting enzyme inhibitorEmerging researchLate-stage development
Also known as (S)-1-(N(2)-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline, Prinivil, Prinzide, Qbrelis+4 more

(S)-1-(N(2)-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline, Prinivil, Prinzide, Qbrelis, Zestoretic, Zestril, Hydrochlorothiazide-Lisinopril, Lisinoprilum.

RxNorm29046ChEMBLCHEMBL419213ATCC09AA03UNIIE7199S1YWR
1
Research papers
5
Active clinical trials
Angiotensin-converting enzyme
Primary target
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

The Effect Of Lisinopril On Polycythemia

Clinical trial2026-05-18Results expected Q3 2028 · ClinicalTrials.gov

A Pilot Randomized Clinical Trial to Assess Feasibility, Safety, and Efficacy of Rapid, Simultaneous Therapy Initiation in Chronic Kidney Disease and Type 2 Diabetes: RAPID-CKD

Clinical trial2026-05-08Results expected Q1 2029 · ClinicalTrials.gov

Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes: A Hybrid Design in a Real-World Setting

Clinical trial2026-05-06Results expected Q2 2028 · ClinicalTrials.gov

A Phase I Study to Determine the Preferred Dose of the Angiotensin Converting Enzyme Inhibitor Lisinopril for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer

Clinical trial2026-01-13Results expected Q1 2028 · ClinicalTrials.gov

Role of Lisinopril in Preventing The Progression of Non-Alcoholic Fatty Liver Disease (NAFLD): Relief-NAFLD

Clinical trial2025-08-08Primary completion · ClinicalTrials.gov

Optimal Management of HIV Infected Adults at Risk for Kidney Complications in Nigeria

Clinical trial2025-02-01Terminated · ClinicalTrials.gov

A Clinical Study to Evaluate the Effect of MK-0616 on Warfarin and Lisinopril Pharmacokinetics in Healthy Adult Participants

Clinical trial2024-06-04Completed · ClinicalTrials.gov

A Phase 3, International, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on CKD Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia

Clinical trial2024-02-07Terminated · ClinicalTrials.gov

Comparison of Optimal Hypertension Regimens (Part of the Ancestry Informative Markers in Hypertension (AIMHY) Programme - AIMHY-INFORM)

Clinical trial2023-10-01Completed · ClinicalTrials.gov

AuTophagy Activation for Cardiomyopathy Due to Anthracycline tReatment (ATACAR) Trial

Clinical trial2023-04-18Withdrawn · ClinicalTrials.gov

A Randomised, Placebo-controlled Pilot Trial to Examine the Efficacy of Interventions to Prevent Left Ventricular Remodelling in Patients Receiving New Pacemaker Implantation (OPT-Prevent-pilot).

Clinical trial2022-12-01Primary completion · ClinicalTrials.gov

A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9.

Research2000-09-01Circulation research

Evidence confidence

1 claim

How strongly the incorporated evidence supports specific clinical claims about this treatment. A confidence figure is a current summary of evidence strength, not a permanent verdict.

Lowers systolic blood pressure in hypertension
61%Moderate confidence
Uncertainty ±17%Evidence coverage: Not yet assessableUpdated 1 October 2023

High point estimate, but substantial uncertainty remains.

Confidence has a moderate point estimate but a wide uncertainty band — the evidence base is still thin.

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Lisinopril
Aliases & brands
(S)-1-(N(2)-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-prolinePrinivilPrinzideQbrelisZestoreticZestrilHydrochlorothiazide-LisinoprilLisinoprilum
RxNorm CUI
29046
ChEMBL ID
CHEMBL419213
ATC codes
C09AA03
UNII
E7199S1YWR
Primary mechanism
Angiotensin-converting enzyme inhibitor

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Angiotensin-converting enzyme
ACE · P12821
INHIBITORAngiotensin-converting enzyme inhibitor

Clinical trials

75 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
75
registered trials across all phases
LATEST COMPLETION 2024
5
Active studies
4
Recruiting
41
Late-stage (III+)
51
Completed
19
Discontinued
PHASE DISTRIBUTIONn = 75
Early Phase 11Phase 118Phase 1 / 21Phase 214Phase 311Phase 416Phase N / A14

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

The Effect Of Lisinopril On Polycythemia

Not yet recruitingPH IVMayo Clinicn=302029

A Pilot Randomized Clinical Trial to Assess Feasibility, Safety, and Efficacy of Rapid, Simultaneous Therapy Initiation in Chronic Kidney Disease and Type 2 Diabetes: RAPID-CKD

Not yet recruitingPH IVBaylor Research Instituten=642029

Comparison of Optimal Hypertension Regimens (Part of the Ancestry Informative Markers in Hypertension (AIMHY) Programme - AIMHY-INFORM)

CompletedPH IVCambridge University Hospitals NHS Foundation Trustn=9402023

Effect of Renin-angiotensin-system (RAS) Blocker Drugs on Chronic Kidney Disease (CKD) Progression in Elderly Patients With Non Proteinuric Nephropathies (PROERCAN01)

Unknown statusPH IVHospital General Universitario Gregorio Marañonn=1062022

A Randomized Clinical Trial of the N-of-1 Approach in Children With Hypertension

CompletedPH IVThe University of Texas Health Science Center, Houstonn=492021

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Clinical Study to Evaluate the Effect of MK-0616 on Warfarin and Lisinopril Pharmacokinetics in Healthy Adult Participants

CompletedPH IMerck Sharp & Dohme LLCn=362024

Comparison of Optimal Hypertension Regimens (Part of the Ancestry Informative Markers in Hypertension (AIMHY) Programme - AIMHY-INFORM)

CompletedPH IVCambridge University Hospitals NHS Foundation Trustn=9402023

Randomized Crossover 2 Period Single Dose Bioequivalence Study of 2 Formulations Lisinopril Tab. 20mg (Pharmtechnology LLC,Belarus) and Zestril® Tab. 20mg (Avara Reims Pharmaceutical Services, France) in Healthy Volunteers Under Fasting Conditions

CompletedPH IPharmtechnology LLCn=382021

A Randomized Clinical Trial of the N-of-1 Approach in Children With Hypertension

CompletedPH IVThe University of Texas Health Science Center, Houstonn=492021

A Double-Blind Pilot Study to Measure the Effect of Lisinopril vs. Placebo on Pulmonary Distress in Patients Receiving External Beam Radiotherapy to the Lung

CompletedPH IIMayo Clinicn=232019

CAndesartan vs LIsinopril Effects on the BRain and Endothelial Function in eXecutive MCI (CALIBREX)

CompletedPH IIEmory Universityn=1762018

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Major research themes1
Renin-Angiotensin System1
Journals, researchers & institutions
Top journals
  • Circulation research1
Leading researchers
  • Acton S1
  • Baronas E1
  • Breitbart RE1
  • Donoghue M1
  • Donovan M1
  • Godbout K1
  • Gosselin M1
  • Hsieh F1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials